Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Who Participates in an Adult Cooperative Group Trial for Adolescent and Young Adults (AYAs)? Baseline Demographic and Psychosocial Characteristics of AYAs Enrolled On Intergroup Trial C10403 for Acute Lymphoblastic Leukemia (ALL)

Lori S. Muffly, MD, Wendy Stock, MD, Kate Breitenbach, APN, Flora Mulkey, Selina Luger, MD, Anjali Advani, MD, Edy Parker, Matthew C Foster, MD, Michaela Liedtke, MD, Reynaldo Garcia, RN, Kristin Coffan, Joselene Sipin-Sayno, Jennifer McNeer, MD, MS, Martin S Tallman, MD, Frederick R. Appelbaum, MD, Richard M. Stone, MD, Richard A. Larson, MD

Blood (2012) 120 (21): 3535.

https://doi.org/10.1182/blood.V120.21.3535.3535

Published: 2012

Journal Articles

Vorinostat in Combination with Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) in Patients with Relapsed/Refractory Multiple Myeloma (R/R MM): Final Results of a Phase I Study,

Peter M. Voorhees, MD, Cristina Gasparetto, MD, Keren Osman, MD, Kristy L. Richards, PhD, MD, Madlyn Ferraro, RN, OCN, CCRC, Reynaldo Garcia, RN, Jennifer MacLean, RN, OCN, Diane Winans, CCRP, Dominic Moore, PhD, John Strader, PA-C, Robert Z. Orlowski, MD, PhD, David Duane Hurd, MD

Blood (2011) 118 (21): 3985.

https://doi.org/10.1182/blood.V118.21.3985.3985

Published: 2011

Journal Articles

Results of a Phase I Study of Vorinostat In Combination with Pegylated Liposomal Doxorubicin and Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma

Peter M Voorhees, M.D., Cristina Gasparetto, MD, Keren Osman, MD, Kristy Richards, PhD, MD, Madlyn Ferraro, RN, OCN, CCRC, Reynaldo Garcia, RN, OCN, Jennifer MacLean, RN, Diane Winans, Dominic Moore, PhD, John Strader, Robert Z. Orlowski, MD, PhD, David Duane Hurd, MD

Blood (2010) 116 (21): 1955.

https://doi.org/10.1182/blood.V116.21.1955.1955

Published: 2010

Journal Articles

Phase I Study of the Novel Surivin and cdc2/CDK1 Inhibitor Terameprocol in Patients with Advanced Leukemias.

Raoul Tibes, MD, PhD, Kevin T. McDonagh, MD, Lazaros Lekakis, MD, Neal Frazer, MD, Scott Mohrland, PhD, Bassett Dawn, RN, Reynaldo Garcia, RN, OCN, Katy Schroeder, RN, Vijayalakshmi Shanmugam, John Carpten, Daniel Von Hoff, MD, FACP, Thomas C. Shea, MD

Blood (2009) 114 (22): 1039.

https://doi.org/10.1182/blood.V114.22.1039.1039

Published: 2009

Journal Articles

Vorinostat in Combination with Pegylated Liposomal Doxorubicin and Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase I Study.

Peter M. Voorhees, MD, Cristina Gasparetto, MD, Kristy L. Richards, PhD, MD, Reynaldo Garcia, RN, OCN, John S. Strader, Madlyn Ferraro, RN, OCN, CCRC, Jennifer MacLean, RN, Diane Winans, Dominic T. Moore, PhD, Andrew Dodd, Matthew C. Foster, MD, Don A. Gabriel, MD, PhD, Thomas C. Shea, Jonathan Serody, MD, Hendrik W. van Deventer, MD, Syed Rizvi, Robert Z. Orlowski, M.D., Ph.D., David D. Hurd, MD

Blood (2009) 114 (22): 306.

https://doi.org/10.1182/blood.V114.22.306.306

Published: 2009

NARROW

Who Participates in an Adult Cooperative Group Trial for Adolescent and Young Adults (AYAs)? Baseline Demographic and Psychosocial Characteristics of AYAs Enrolled On Intergroup Trial C10403 for Acute Lymphoblastic Leukemia (ALL)

Vorinostat in Combination with Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) in Patients with Relapsed/Refractory Multiple Myeloma (R/R MM): Final Results of a Phase I Study,

Results of a Phase I Study of Vorinostat In Combination with Pegylated Liposomal Doxorubicin and Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma

Phase I Study of the Novel Surivin and cdc2/CDK1 Inhibitor Terameprocol in Patients with Advanced Leukemias.

Vorinostat in Combination with Pegylated Liposomal Doxorubicin and Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase I Study.

Email alerts

ASH Publications

American Society of Hematology

Who Participates in an Adult Cooperative Group Trial for Adolescent and Young Adults (AYAs)? Baseline Demographic and Psychosocial Characteristics of AYAs Enrolled On Intergroup Trial C10403 for Acute Lymphoblastic Leukemia (ALL)

Vorinostat in Combination with Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) in Patients with Relapsed/Refractory Multiple Myeloma (R/R MM): Final Results of a Phase I Study,

Results of a Phase I Study of Vorinostat In Combination with Pegylated Liposomal Doxorubicin and Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma

Phase I Study of the Novel Surivin and cdc2/CDK1 Inhibitor Terameprocol in Patients with Advanced Leukemias.

Vorinostat in Combination with Pegylated Liposomal Doxorubicin and Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase I Study.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only